Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.

The National Institutes of Health-funded IMPACC (IMmunoPhenotyping Assessment in a COVID-19 Cohort) evaluated longitudinal clinical and immunological features of human patients hospitalized for COVID-19. This study focuses on comparing the novel NULISAseq assay with the Olink platform using a subset of participants to assess their efficacy in predicting COVID-19 severity and understanding immune response dynamics. Our findings reveal that NULISAseq could provide superior detectability and dynamic range across various targets. Elastic net analysis demonstrated that specific proteins, including amphiregulin, effectively predict COVID-19 severity from sera at admission (samples drawn within 96 h of admission), with a test area under the curve of 0.84. Longitudinal analysis identified significant differences in multiple targets, including IL-5 and interferons, between low- and high-severity groups over time. Additionally, association rule mining suggested potential early markers predictive of later immune cell changes. These findings emphasize the potential of NULISAseq for comprehensive profiling, early prediction, and identification of targeted therapeutic interventions in COVID-19.